REFRACTORY OF WELL-DIFFERENTIATED THYROID CANCER TO THE TREATMENT WITH RADIOACTIVE IODINE
https://doi.org/10.17650/2222-1468-2013-0-3-11-15
Abstract
Resistance of well-differentiated distant metastases to radioactive iodine treatment severely deteriorate survival prognosis of patients. Chemotherapy (doxorubicin and combinations) and retinoid acid analoques (isotretinоin, roaccutan) implimentation did not allow to recommend them as a therapy of choice. Effectiveness of several multikinase inhibitors (vandetanib, sorafenib, sunitinib) was confirmed in phase II clinical trials. In result of phase III clinical trial of sorafenib (reported on ASCO’2013, Chicago, USA) its therapeutic efficacy in patient with iodine-refractory well-differentiated thyroid cancer was affirmed.
About the Author
P. O. Rumyantsev
Endocrinology Research Center, Ministry of Health of Russia, Moscow
Russian Federation
Russian Federation
References
1. Румянцев П.О., Ильин А.А., Румянцева У.В., Саенко В.А. Рак щитовидной железы. Современные подходы к диагностике и лечению. М.: ГЭОТАР-Медиа, 2009.
2. Durante C., Haddy N., Baudin E. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;8:2892–9.
3. Schlumberger M., Lacroix L., Russo D. et al. Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nat Clin Pract Endocrinol Metab 2007;3:260–9.
4. Schlumberger M.J. Papillary and follicular thyroid carcinoma. N Engl J Med 1998;5:297–306. 5. Hodak S.P., Carty S.E. Radioiodineresistant differentiated thyroid cancer: hope for the future. Oncology 2009;9:775–6.
5. Capdevila J., Argiles G., RodriguezFrexinos V. et al. New approaches in the management of radioiodine-refractory thyroid cancer: the molecular targeted therapy era. Discov Med 2010;45:153–62.
Review
For citations:
Rumyantsev P.O. REFRACTORY OF WELL-DIFFERENTIATED THYROID CANCER TO THE TREATMENT WITH RADIOACTIVE IODINE. Head and Neck Tumors (HNT). 2013;(3):11-15. (In Russ.) https://doi.org/10.17650/2222-1468-2013-0-3-11-15
Views:
904
Email this article 